NEWS・COLUMN
We send the latest information from SMC Laboratories.
Clear Negative Correlation Between FVC and Ashcroft Score in Bleomycin-Induced Lung Fibrosis Model
In preclinical drug development for fibrotic lung diseases, the ability to quantitatively and reproducibly ass…
New Model Launch: Introduction of the Rat CCl₄-Induced Acute Liver Injury Model
SMC Laboratories is pleased to announce the launch of a new in vivo platform: the rat CCl₄ (carbon tetrachlori…
Launch of Rat Disease Model Services
To better meet evolving research needs, SMC Laboratories has officially launched a lineup of preclinical rat d…
Chitinase-1 Inhibition Attenuates MASH Progression: A Novel Therapeutic Approach via Metabolic Reprogramming
In May 2025, a collaborative research team from OncoArendi Therapeutics and academic institutions in Poland pu…
A Preclinical Package to Maximize the Value of Your MASH Candidate
Featured in Frontiers in Immunology: A Preclinical Package to Maximize the Value of Your MASH Candidate…
Exhibition Announcement: SMC Laboratories to Exhibit at the 61st Annual Meeting of the Japan Society of Hepatology
SMC Laboratories, Inc. is pleased to announce our participation in the 61st Annual Meeting of the Japan Societ…
Hepatocellular Senescence Linked to Liver Cancer Development: Sirolimus Shows Preventive Potential in Preclinical Study
A new study published in Human Cell by researchers at the University of Nottingham highlights the role of hepa…
IL-18 Binding Protein Shows Promise in Suppressing Fibrosis in MASH: New Study Published in Cell Reports Medicine
A recent study published in Cell Reports Medicine (April 2025) reports that treatment with an IL-18 binding pr…
Devonian Reports Positive Results in MASH Liver Study
In a great collaboration with Devonian Health Group Inc., we are happy to demonstrate preclinical proof of con…
New possibilities for MASH treatment: Confirmation of the effectiveness of 2-hydroxybenzylamine
A new study published in the Feb 2025 issue of Nutrients highlights the therapeutic promise of 2-hydroxybenzyl…
CytoDyn Reports Significant Fibrosis Reversal in SMC Lab Studies
In a great collaboration with CytoDyn Inc., we are pleased to share promising preclinical results demonstratin…
A New Approach to Pulmonary Fibrosis Research: Introducing SMC Laboratories’ IPF Model
SMC Laboratories, Inc. (Tokyo, Japan) is a preclinical CRO specializing in pharmacological evaluations using d…